SlideShare une entreprise Scribd logo
1  sur  19
Vulnerable Plaque SymposiumVulnerable Plaque Symposium
Patients with High CRP & HighPatients with High CRP & High
CT Calcium Score are at Higher Risk:CT Calcium Score are at Higher Risk:
How Can Calcium ScoreHow Can Calcium Score
Improve Your Practice?Improve Your Practice?
John A. Rumberger, PhD, MD, FACCJohn A. Rumberger, PhD, MD, FACC
Clinical Professor of Medicine, Ohio State UniversityClinical Professor of Medicine, Ohio State University
Medical DirectorMedical Director
Physician’s Prevention and Wellness CenterPhysician’s Prevention and Wellness Center
Columbus, OhioColumbus, Ohio
Chicago, ILChicago, IL
March 29, 2003March 29, 2003© 2003 John A Rumberger, MD
1.25
1.6
1.6
1.8
2.15
2.35
2.5
5
0 2 4 6 8 10
Lp(a)
Homocysteine
TC
Fibr
t-PA Ag
TC/HDL
hs-CRP
hs-CRP + TC/HDL
RR in men from the
Physicians Health Study
Risk of MI in Apparently Healthy PeopleRisk of MI in Apparently Healthy People
Values in the Highest Quartile Compared to Lowest Quartile
hs C-Reactive Proteinhs C-Reactive Protein
AtAt PRESENTPRESENT the following has been established:the following has been established:
o Values in the upper tercile (or quartile) confer a 2+ risk MI/SCDValues in the upper tercile (or quartile) confer a 2+ risk MI/SCD
o Marker likely for “endothelial dysfunction”Marker likely for “endothelial dysfunction”
o May have a role in “promoting atherogenesis”May have a role in “promoting atherogenesis”
o Values altered by:Values altered by: Increased By Decreased ByIncreased By Decreased By
Elevated BP ETOH consumptionElevated BP ETOH consumption
BMI Aerobic exerciseBMI Aerobic exercise
Metabolic syndrome Weight lossMetabolic syndrome Weight loss
Hormone use Medications:Hormone use Medications:
Chronic infections statins, fibrates,Chronic infections statins, fibrates,
Chronic inflammation niacinChronic inflammation niacin
hs C-Reactive Proteinhs C-Reactive Protein
o May or may not be related to the severity or extent of diseaseMay or may not be related to the severity or extent of disease
o This could be due to differences in chronicity or “pattern”This could be due to differences in chronicity or “pattern”
o CRP may be more related to “acceleration of atherosclerosis”CRP may be more related to “acceleration of atherosclerosis”
rather than its extentrather than its extent
VTVT
VT = “vulnerable threshold”VT = “vulnerable threshold”
““vulnerability”vulnerability”
TimeTime
Patient APatient A
Patient BPatient B
MI/SCDMI/SCD
The “Vulnerable Threshold”
CRPCRP
CRPCRP
CRPCRP
©
© 2003 John A Rumberger, MD
©
CT Coronary Artery CalciumCT Coronary Artery Calcium
No CalcificationNo Calcification Severe CalcificationSevere Calcification
Left Main
LAD
LCX
AoAo
LALA
PAPA
Coronary Calcium Area by EBT andCoronary Calcium Area by EBT and
Coronary Artery Plaque AreaCoronary Artery Plaque Area
0
2
4
6
8
10
12
14
16
0 2 4 6 8
Square Root Sum of Calcium Areas
SquareRootSumof
PlaqueAreas
Rumberger, Circ 1995:92:2157-62
n = 38n = 38
r = 0.90r = 0.90
p < .001p < .001
No. of coronary segments/pt. with plaques (IVUS)No. of coronary segments/pt. with plaques (IVUS)
0 1 2 3 4 5 6 7
No. of calcifiedNo. of calcified
coronarycoronary
segments/pt.segments/pt.
(EBCT)(EBCT)
0
1
2
3
4
5
6
7
Y = -0.67 + (0.90 * X)
r = 0.86
p < 0.0001 N = 40 patients
total of 222 coronary
segments examined
# of segments with EBT calcium vs. # of segments with any plaque# of segments with EBT calcium vs. # of segments with any plaque
Schmermund et alSchmermund et al
AJC 1998; 81:AJC 1998; 81:
141-146141-146
EBT and Coronary Artery CalciumEBT and Coronary Artery Calcium
 Define the extent of ASO disease?Define the extent of ASO disease?
YESYES
 The amount of calciumThe amount of calcium correlates DIRECTLYcorrelates DIRECTLY toto
the amount of measurable coronary disease by:the amount of measurable coronary disease by:
1) direct histopathologic comparison1) direct histopathologic comparison
2) with intravascular ultrasound2) with intravascular ultrasound
3
4.4
8.8
0
2
4
6
8
10
Score 0 Score 1-15 Score 16-
80
Score 81-
270
Score
>271
Relative Risk for Future CV Events using EBCT:Relative Risk for Future CV Events using EBCT:
926 initially asymptomatic patients926 initially asymptomatic patients
1st Quartile1st Quartile 2nd Quartile2nd Quartile 3rd Quartile3rd Quartile 4th Quartile4th Quartile
* AdjustedAdjusted for age, gender, hypertension, past/current smoking, and diabetesfor age, gender, hypertension, past/current smoking, and diabetes
Wong and Detrano, et al [Am J Cardiol 2000;86:495-498Wong and Detrano, et al [Am J Cardiol 2000;86:495-498
RelativeRisk(RR)RelativeRisk(RR)
Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients:
EBTEBT
Raggi et al AHJ 2001;141:193-199Raggi et al AHJ 2001;141:193-199
0.36 0.51 0.71
0.99
1.38
1.92
2.64
3.62
4.9
6.54
0
1
2
3
4
5
6
7
0 10 20 30 40 50 60 70 80 90
Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score
676 initially asymptomatic patients676 initially asymptomatic patients
3232++7 months f/u7 months f/u
AnnualAnnual AbsoluteAbsolute RiskRisk
EBT CVSEBT CVS (volume score)(volume score) Progression and MIProgression and MI
Raggi, Shaw, Callister, Budoff; JACC 2003Raggi, Shaw, Callister, Budoff; JACC 2003 (retrospective analysis)(retrospective analysis)
0
10
20
30
40
50
60
No MI MI
MeanChangeinCVS/yearMeanChangeinCVS/year
26+1.5%
47.5+7.5% *
n = 833, 2.1+1.4 yr f/u,
45 documented MI (2.2%/yr)
Stepwise Cox Model
Independent Predictors of MI
 Elevated cholesterol
 Diabetes
 Initial EBT-CVS
 % Change in EBT-CVS
Initially asymptomatic patients with CVS > 30 and repeat EBT Scans
Coronary Artery CalcificationCoronary Artery Calcification
AtAt PRESENTPRESENT the following has been established:the following has been established:
o Coronary calcium IS AtherosclerosisCoronary calcium IS Atherosclerosis
o The magnitude of the calcium score relates to the severity of ASO diseaseThe magnitude of the calcium score relates to the severity of ASO disease
o The calcium score as well as the percentile rank provide informationThe calcium score as well as the percentile rank provide information
in which to view risk factors, rather than the other way aroundin which to view risk factors, rather than the other way around
o The data on examining progression of CAD with CT are consistent withThe data on examining progression of CAD with CT are consistent with
the potential for the calcium score/rank to be used as the “goal” of therapythe potential for the calcium score/rank to be used as the “goal” of therapy
RR of non-fatal MI/Cardiac Death:
EBT Score and hs-CRP
6.3 4.3
1.74.9
1.8 1
0
2
4
6
8
High CAC Med. CAC Low CAC
Lowest quartile
hs-CRP
Highest quartile
hs-CRP
Park et al.
Circ. 2002;106-2073-2077
6.3
RelativeRiskRelativeRisk
6.4 yr. f/u, n = 967
initially asymptomatic,
non-diabetic individuals
Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients:
EBTEBT
0
1
2
3
4
5
6
7
0 10 20 30 40 50 60 70 80 90
Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score
LowLow
RiskRisk
IntermediateIntermediate
RiskRisk
HighHigh
RiskRisk
Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients:
EBTEBT
0
1
2
3
4
5
6
7
0 10 20 30 40 50 60 70 80 90
Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score
LowLow
RiskRisk
IntermediateIntermediate
RiskRisk
HighHigh
RiskRisk
CRP
CRP
Clinical Questions in PreventionClinical Questions in Prevention
In the asymptomatic individual
How aggressive should I be?
 Primary versus secondary prev. goals
How closely should I follow up?
 Routine versus close & repeat testing
hs-CRP CAC Range Level of Aggression, f/u
< 1 mg/L
> 1-3 mg/L
> 3 mg/L
hs-CRP & CAC Scoringhs-CRP & CAC Scoring
Value Range Percentile Range Aggression Clinical f/u
Low
Low
Low
Mod.
Mod.
Mod.
High
High
High
<25th
Low
>25th
-<75th
Intermed.
>75th
High
<25th
Low
>25th
-<75th
Intermed.
>75th
High
<25th
Low
>25th
-<75th
Intermed.
>75th
High
Primary Routine
Primary Routine
Secondary Close
Primary Routine
Primary Close
Secondary Close
Primary Close
Secondary Close
Secondary Close
hs-CRP & CAC Scoringhs-CRP & CAC Scoring
In “intermediate” risk asymptomatic individualsIn “intermediate” risk asymptomatic individuals
CAC Scanning with CTCAC Scanning with CT
&&
hs-CRP testinghs-CRP testing
areare ComplementaryComplementary to each otherto each other
and the combination of bothand the combination of both
can be used to refinecan be used to refine
Clinical-Decision making in such patientsClinical-Decision making in such patients

Contenu connexe

Tendances

Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
incucai_isodp
 
SIDE EFFECTS OF TKIs
SIDE EFFECTS OF TKIsSIDE EFFECTS OF TKIs
SIDE EFFECTS OF TKIs
spa718
 
Anticoagulación en Mieloma Múltiple
Anticoagulación en Mieloma MúltipleAnticoagulación en Mieloma Múltiple
Anticoagulación en Mieloma Múltiple
evelyn-mejia
 

Tendances (16)

Cancer related anemia
Cancer related anemiaCancer related anemia
Cancer related anemia
 
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
Alirocumab effect on new-onset or worsening diabetes, blood glucose, and HbA1c.
 
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
Federico Villamil - Argentina - Tuesday 29 - Liver Transplantation Towards Ne...
 
Novel biomarkers in ovarian carcinoma
Novel biomarkers in ovarian carcinomaNovel biomarkers in ovarian carcinoma
Novel biomarkers in ovarian carcinoma
 
Crizo
CrizoCrizo
Crizo
 
June 2016 ASCO in Review #CRCWebinar
June 2016 ASCO in Review #CRCWebinar June 2016 ASCO in Review #CRCWebinar
June 2016 ASCO in Review #CRCWebinar
 
SIDE EFFECTS OF TKIs
SIDE EFFECTS OF TKIsSIDE EFFECTS OF TKIs
SIDE EFFECTS OF TKIs
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Dr fuster's slides part i
Dr fuster's slides  part iDr fuster's slides  part i
Dr fuster's slides part i
 
Familial predisposition for colorectal cancers: Who to screen?
Familial predisposition for colorectal cancers: Who to screen?Familial predisposition for colorectal cancers: Who to screen?
Familial predisposition for colorectal cancers: Who to screen?
 
Astellas meeting, crpc- what we have in 2019
Astellas   meeting, crpc- what we have in 2019Astellas   meeting, crpc- what we have in 2019
Astellas meeting, crpc- what we have in 2019
 
Crpc the paradigm of sequence
Crpc  the paradigm of sequenceCrpc  the paradigm of sequence
Crpc the paradigm of sequence
 
Improve it slides
Improve it slidesImprove it slides
Improve it slides
 
Anticoagulación en Mieloma Múltiple
Anticoagulación en Mieloma MúltipleAnticoagulación en Mieloma Múltiple
Anticoagulación en Mieloma Múltiple
 
BEYOND BELATACEPT
BEYOND BELATACEPT BEYOND BELATACEPT
BEYOND BELATACEPT
 
Aeha2004 crp lppla2newtemplate-koenig
Aeha2004 crp lppla2newtemplate-koenigAeha2004 crp lppla2newtemplate-koenig
Aeha2004 crp lppla2newtemplate-koenig
 

En vedette

En vedette (20)

Vp watch editorial - v2 n6- 2002
Vp watch   editorial - v2 n6- 2002Vp watch   editorial - v2 n6- 2002
Vp watch editorial - v2 n6- 2002
 
Vpiii lobby-02
Vpiii lobby-02Vpiii lobby-02
Vpiii lobby-02
 
Vp slides
Vp slidesVp slides
Vp slides
 
Vulnerable patient mar 04
Vulnerable patient mar 04Vulnerable patient mar 04
Vulnerable patient mar 04
 
Vulnerable patient slides without movies
Vulnerable patient slides without moviesVulnerable patient slides without movies
Vulnerable patient slides without movies
 
Vp meeting orlando2003_new template
Vp meeting orlando2003_new templateVp meeting orlando2003_new template
Vp meeting orlando2003_new template
 
Vpschoenhagen
VpschoenhagenVpschoenhagen
Vpschoenhagen
 
Glasgow FCCLA At the Table
Glasgow FCCLA At the TableGlasgow FCCLA At the Table
Glasgow FCCLA At the Table
 
Hour of Code CS Class
Hour of Code CS ClassHour of Code CS Class
Hour of Code CS Class
 
Hour of Code Kickoff Assembly
Hour of Code Kickoff AssemblyHour of Code Kickoff Assembly
Hour of Code Kickoff Assembly
 
Vp.org cimit harvard
Vp.org cimit harvardVp.org cimit harvard
Vp.org cimit harvard
 
Vp watch editorial - v2 n3- 2002
Vp watch   editorial - v2 n3- 2002Vp watch   editorial - v2 n3- 2002
Vp watch editorial - v2 n3- 2002
 
Why should UV22 catch your eye?
Why should UV22 catch your eye?Why should UV22 catch your eye?
Why should UV22 catch your eye?
 
Blenderアーチストに捧げる10の言葉
Blenderアーチストに捧げる10の言葉Blenderアーチストに捧げる10の言葉
Blenderアーチストに捧げる10の言葉
 
Vp symposium31602
Vp symposium31602Vp symposium31602
Vp symposium31602
 
タブレットでわくわくプログラミング体験(公開版)
タブレットでわくわくプログラミング体験(公開版)タブレットでわくわくプログラミング体験(公開版)
タブレットでわくわくプログラミング体験(公開版)
 
Hour Of Code : A Sample Lesson With Links To Activites
Hour Of Code : A Sample Lesson With Links To ActivitesHour Of Code : A Sample Lesson With Links To Activites
Hour Of Code : A Sample Lesson With Links To Activites
 
Quando a competição de empresas não maduras reduz seu custo do capital?
Quando a competição de empresas não maduras reduz seu custo do capital?Quando a competição de empresas não maduras reduz seu custo do capital?
Quando a competição de empresas não maduras reduz seu custo do capital?
 
Supplier Evaluation & Selection
Supplier Evaluation & SelectionSupplier Evaluation & Selection
Supplier Evaluation & Selection
 
Divulgação do PPGCC e Eventos da UFPB 2015
Divulgação do PPGCC e Eventos da UFPB 2015Divulgação do PPGCC e Eventos da UFPB 2015
Divulgação do PPGCC e Eventos da UFPB 2015
 

Similaire à Vp presentation jar 3 29 03

251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
SHAPE Society
 
Thorax cardio coeur heart evaluation asymptomatic smoker p douek
Thorax cardio coeur heart evaluation asymptomatic smoker p douekThorax cardio coeur heart evaluation asymptomatic smoker p douek
Thorax cardio coeur heart evaluation asymptomatic smoker p douek
JFIM
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
MedicineAndHealthUSA
 
CT coronary angiography Pay Now, Benefits May Follow
CT coronary angiography Pay Now, Benefits May Follow CT coronary angiography Pay Now, Benefits May Follow
CT coronary angiography Pay Now, Benefits May Follow
piuonesto
 

Similaire à Vp presentation jar 3 29 03 (20)

Harvey hecht md aeha sat
Harvey hecht md aeha satHarvey hecht md aeha sat
Harvey hecht md aeha sat
 
136 framingham model and coronary events
136 framingham model and coronary events136 framingham model and coronary events
136 framingham model and coronary events
 
Budoff shape-1105
Budoff shape-1105Budoff shape-1105
Budoff shape-1105
 
093 multi slice fast ct
093 multi slice fast ct093 multi slice fast ct
093 multi slice fast ct
 
093 multi slice fast ct
093 multi slice fast ct093 multi slice fast ct
093 multi slice fast ct
 
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad ateroscleróticaDr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
Dr. Jose Luis Zamorano. Evolución no invasiva de la enfermedad aterosclerótica
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
Rumberger 2nd vp symposium 3 6 04
Rumberger 2nd vp symposium 3 6 04Rumberger 2nd vp symposium 3 6 04
Rumberger 2nd vp symposium 3 6 04
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
Es v2n43
Es v2n43Es v2n43
Es v2n43
 
Thorax cardio coeur heart evaluation asymptomatic smoker p douek
Thorax cardio coeur heart evaluation asymptomatic smoker p douekThorax cardio coeur heart evaluation asymptomatic smoker p douek
Thorax cardio coeur heart evaluation asymptomatic smoker p douek
 
Aeha2004 crp lppla2newtemplate
Aeha2004 crp lppla2newtemplateAeha2004 crp lppla2newtemplate
Aeha2004 crp lppla2newtemplate
 
Cardio respiratory nuclear imaging ihab - copy
Cardio respiratory nuclear imaging ihab - copyCardio respiratory nuclear imaging ihab - copy
Cardio respiratory nuclear imaging ihab - copy
 
Lipid lowering therapy in CKD
Lipid lowering therapy in CKDLipid lowering therapy in CKD
Lipid lowering therapy in CKD
 
Stein cimt for shape 11-05
Stein   cimt for shape 11-05Stein   cimt for shape 11-05
Stein cimt for shape 11-05
 
Dr falk's slides part ii
Dr falk's slides  part iiDr falk's slides  part ii
Dr falk's slides part ii
 
Slides naqvi
Slides naqviSlides naqvi
Slides naqvi
 
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...Hypertension and Diabetic Kidney Disease Progression 	 Hypertension and Diabe...
Hypertension and Diabetic Kidney Disease Progression Hypertension and Diabe...
 
CT coronary angiography Pay Now, Benefits May Follow
CT coronary angiography Pay Now, Benefits May Follow CT coronary angiography Pay Now, Benefits May Follow
CT coronary angiography Pay Now, Benefits May Follow
 

Plus de Society for Heart Attack Prevention and Eradication

Plus de Society for Heart Attack Prevention and Eradication (20)

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi PresentationAHA SHAPE Symposium 2017 Dr. Naghavi Presentation
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
 
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner PresentationAHA SHAPE Symposium 2017 Dr. Kloner Presentation
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
 
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland PresentationAHA SHAPE Symposium 2017 Dr. Greenland Presentation
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
 
AHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen PresentationAHA SHAPE Symposium 2017 Dr. Yen Presentation
AHA SHAPE Symposium 2017 Dr. Yen Presentation
 
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka PresentationAHA SHAPE Symposium 2017 Dr. Slomka Presentation
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
 
Vu lplaque1 pasterkamp
Vu lplaque1 pasterkampVu lplaque1 pasterkamp
Vu lplaque1 pasterkamp
 
Vulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patientVulnerable plaque vulnerable patient
Vulnerable plaque vulnerable patient
 
Vulnerable plaque overview
Vulnerable plaque overviewVulnerable plaque overview
Vulnerable plaque overview
 
Vulnerable patient talk in poland
Vulnerable patient talk in polandVulnerable patient talk in poland
Vulnerable patient talk in poland
 
Vulnerable (thrombogenic blood
Vulnerable (thrombogenic bloodVulnerable (thrombogenic blood
Vulnerable (thrombogenic blood
 
Vuln shape aha 2005
Vuln shape aha 2005Vuln shape aha 2005
Vuln shape aha 2005
 
Vuln plaque poster burke
Vuln plaque poster burkeVuln plaque poster burke
Vuln plaque poster burke
 
Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-Vp watch editorial_slide 25short-
Vp watch editorial_slide 25short-
 
Vp watch editorial_slide25
Vp watch editorial_slide25Vp watch editorial_slide25
Vp watch editorial_slide25
 
Vp watch editorial_slide25short-
Vp watch editorial_slide25short-Vp watch editorial_slide25short-
Vp watch editorial_slide25short-
 
Vp watch2002
Vp watch2002Vp watch2002
Vp watch2002
 
Vp
VpVp
Vp
 
Vp texas by yuan
Vp texas by yuanVp texas by yuan
Vp texas by yuan
 
Vp watch editorial - v2 n2- 2002
Vp watch   editorial - v2 n2- 2002Vp watch   editorial - v2 n2- 2002
Vp watch editorial - v2 n2- 2002
 
Vp watch editorial - v2 n4- 2002
Vp watch   editorial - v2 n4- 2002Vp watch   editorial - v2 n4- 2002
Vp watch editorial - v2 n4- 2002
 

Dernier

Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
mahaiklolahd
 
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
Call Girls In Delhi Whatsup 9873940964 Enjoy Unlimited Pleasure
 

Dernier (20)

All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
 
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
 
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
Model Call Girls In Chennai WhatsApp Booking 7427069034 call girl service 24 ...
 
Call Girls Shimla Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Shimla Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Shimla Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Shimla Just Call 8617370543 Top Class Call Girl Service Available
 
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
Mumbai ] (Call Girls) in Mumbai 10k @ I'm VIP Independent Escorts Girls 98333...
 
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls  * UPA...
Call Girl in Indore 8827247818 {LowPrice} ❤️ (ahana) Indore Call Girls * UPA...
 
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
🌹Attapur⬅️ Vip Call Girls Hyderabad 📱9352852248 Book Well Trand Call Girls In...
 
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
8980367676 Call Girls In Ahmedabad Escort Service Available 24×7 In Ahmedabad
 
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service AvailableTrichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
 
Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...
Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...
Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...
 
Call Girls Hosur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Hosur Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Hosur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Hosur Just Call 9630942363 Top Class Call Girl Service Available
 
Top Rated Bangalore Call Girls Richmond Circle ⟟ 9332606886 ⟟ Call Me For Ge...
Top Rated Bangalore Call Girls Richmond Circle ⟟  9332606886 ⟟ Call Me For Ge...Top Rated Bangalore Call Girls Richmond Circle ⟟  9332606886 ⟟ Call Me For Ge...
Top Rated Bangalore Call Girls Richmond Circle ⟟ 9332606886 ⟟ Call Me For Ge...
 
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...Top Rated Bangalore Call Girls Mg Road ⟟   9332606886 ⟟ Call Me For Genuine S...
Top Rated Bangalore Call Girls Mg Road ⟟ 9332606886 ⟟ Call Me For Genuine S...
 
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
Manyata Tech Park ( Call Girls ) Bangalore ✔ 6297143586 ✔ Hot Model With Sexy...
 
Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...
Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...
Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...
 
Call Girls Vadodara Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Vadodara Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Vadodara Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Vadodara Just Call 8617370543 Top Class Call Girl Service Available
 
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...Russian Call Girls Service  Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
Russian Call Girls Service Jaipur {8445551418} ❤️PALLAVI VIP Jaipur Call Gir...
 
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
 

Vp presentation jar 3 29 03

  • 1. Vulnerable Plaque SymposiumVulnerable Plaque Symposium Patients with High CRP & HighPatients with High CRP & High CT Calcium Score are at Higher Risk:CT Calcium Score are at Higher Risk: How Can Calcium ScoreHow Can Calcium Score Improve Your Practice?Improve Your Practice? John A. Rumberger, PhD, MD, FACCJohn A. Rumberger, PhD, MD, FACC Clinical Professor of Medicine, Ohio State UniversityClinical Professor of Medicine, Ohio State University Medical DirectorMedical Director Physician’s Prevention and Wellness CenterPhysician’s Prevention and Wellness Center Columbus, OhioColumbus, Ohio Chicago, ILChicago, IL March 29, 2003March 29, 2003© 2003 John A Rumberger, MD
  • 2. 1.25 1.6 1.6 1.8 2.15 2.35 2.5 5 0 2 4 6 8 10 Lp(a) Homocysteine TC Fibr t-PA Ag TC/HDL hs-CRP hs-CRP + TC/HDL RR in men from the Physicians Health Study Risk of MI in Apparently Healthy PeopleRisk of MI in Apparently Healthy People Values in the Highest Quartile Compared to Lowest Quartile
  • 3. hs C-Reactive Proteinhs C-Reactive Protein AtAt PRESENTPRESENT the following has been established:the following has been established: o Values in the upper tercile (or quartile) confer a 2+ risk MI/SCDValues in the upper tercile (or quartile) confer a 2+ risk MI/SCD o Marker likely for “endothelial dysfunction”Marker likely for “endothelial dysfunction” o May have a role in “promoting atherogenesis”May have a role in “promoting atherogenesis” o Values altered by:Values altered by: Increased By Decreased ByIncreased By Decreased By Elevated BP ETOH consumptionElevated BP ETOH consumption BMI Aerobic exerciseBMI Aerobic exercise Metabolic syndrome Weight lossMetabolic syndrome Weight loss Hormone use Medications:Hormone use Medications: Chronic infections statins, fibrates,Chronic infections statins, fibrates, Chronic inflammation niacinChronic inflammation niacin
  • 4. hs C-Reactive Proteinhs C-Reactive Protein o May or may not be related to the severity or extent of diseaseMay or may not be related to the severity or extent of disease o This could be due to differences in chronicity or “pattern”This could be due to differences in chronicity or “pattern” o CRP may be more related to “acceleration of atherosclerosis”CRP may be more related to “acceleration of atherosclerosis” rather than its extentrather than its extent
  • 5. VTVT VT = “vulnerable threshold”VT = “vulnerable threshold” ““vulnerability”vulnerability” TimeTime Patient APatient A Patient BPatient B MI/SCDMI/SCD The “Vulnerable Threshold” CRPCRP CRPCRP CRPCRP © © 2003 John A Rumberger, MD ©
  • 6. CT Coronary Artery CalciumCT Coronary Artery Calcium No CalcificationNo Calcification Severe CalcificationSevere Calcification Left Main LAD LCX AoAo LALA PAPA
  • 7. Coronary Calcium Area by EBT andCoronary Calcium Area by EBT and Coronary Artery Plaque AreaCoronary Artery Plaque Area 0 2 4 6 8 10 12 14 16 0 2 4 6 8 Square Root Sum of Calcium Areas SquareRootSumof PlaqueAreas Rumberger, Circ 1995:92:2157-62 n = 38n = 38 r = 0.90r = 0.90 p < .001p < .001
  • 8. No. of coronary segments/pt. with plaques (IVUS)No. of coronary segments/pt. with plaques (IVUS) 0 1 2 3 4 5 6 7 No. of calcifiedNo. of calcified coronarycoronary segments/pt.segments/pt. (EBCT)(EBCT) 0 1 2 3 4 5 6 7 Y = -0.67 + (0.90 * X) r = 0.86 p < 0.0001 N = 40 patients total of 222 coronary segments examined # of segments with EBT calcium vs. # of segments with any plaque# of segments with EBT calcium vs. # of segments with any plaque Schmermund et alSchmermund et al AJC 1998; 81:AJC 1998; 81: 141-146141-146
  • 9. EBT and Coronary Artery CalciumEBT and Coronary Artery Calcium  Define the extent of ASO disease?Define the extent of ASO disease? YESYES  The amount of calciumThe amount of calcium correlates DIRECTLYcorrelates DIRECTLY toto the amount of measurable coronary disease by:the amount of measurable coronary disease by: 1) direct histopathologic comparison1) direct histopathologic comparison 2) with intravascular ultrasound2) with intravascular ultrasound
  • 10. 3 4.4 8.8 0 2 4 6 8 10 Score 0 Score 1-15 Score 16- 80 Score 81- 270 Score >271 Relative Risk for Future CV Events using EBCT:Relative Risk for Future CV Events using EBCT: 926 initially asymptomatic patients926 initially asymptomatic patients 1st Quartile1st Quartile 2nd Quartile2nd Quartile 3rd Quartile3rd Quartile 4th Quartile4th Quartile * AdjustedAdjusted for age, gender, hypertension, past/current smoking, and diabetesfor age, gender, hypertension, past/current smoking, and diabetes Wong and Detrano, et al [Am J Cardiol 2000;86:495-498Wong and Detrano, et al [Am J Cardiol 2000;86:495-498 RelativeRisk(RR)RelativeRisk(RR)
  • 11. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients: EBTEBT Raggi et al AHJ 2001;141:193-199Raggi et al AHJ 2001;141:193-199 0.36 0.51 0.71 0.99 1.38 1.92 2.64 3.62 4.9 6.54 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score 676 initially asymptomatic patients676 initially asymptomatic patients 3232++7 months f/u7 months f/u AnnualAnnual AbsoluteAbsolute RiskRisk
  • 12. EBT CVSEBT CVS (volume score)(volume score) Progression and MIProgression and MI Raggi, Shaw, Callister, Budoff; JACC 2003Raggi, Shaw, Callister, Budoff; JACC 2003 (retrospective analysis)(retrospective analysis) 0 10 20 30 40 50 60 No MI MI MeanChangeinCVS/yearMeanChangeinCVS/year 26+1.5% 47.5+7.5% * n = 833, 2.1+1.4 yr f/u, 45 documented MI (2.2%/yr) Stepwise Cox Model Independent Predictors of MI  Elevated cholesterol  Diabetes  Initial EBT-CVS  % Change in EBT-CVS Initially asymptomatic patients with CVS > 30 and repeat EBT Scans
  • 13. Coronary Artery CalcificationCoronary Artery Calcification AtAt PRESENTPRESENT the following has been established:the following has been established: o Coronary calcium IS AtherosclerosisCoronary calcium IS Atherosclerosis o The magnitude of the calcium score relates to the severity of ASO diseaseThe magnitude of the calcium score relates to the severity of ASO disease o The calcium score as well as the percentile rank provide informationThe calcium score as well as the percentile rank provide information in which to view risk factors, rather than the other way aroundin which to view risk factors, rather than the other way around o The data on examining progression of CAD with CT are consistent withThe data on examining progression of CAD with CT are consistent with the potential for the calcium score/rank to be used as the “goal” of therapythe potential for the calcium score/rank to be used as the “goal” of therapy
  • 14. RR of non-fatal MI/Cardiac Death: EBT Score and hs-CRP 6.3 4.3 1.74.9 1.8 1 0 2 4 6 8 High CAC Med. CAC Low CAC Lowest quartile hs-CRP Highest quartile hs-CRP Park et al. Circ. 2002;106-2073-2077 6.3 RelativeRiskRelativeRisk 6.4 yr. f/u, n = 967 initially asymptomatic, non-diabetic individuals
  • 15. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients: EBTEBT 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score LowLow RiskRisk IntermediateIntermediate RiskRisk HighHigh RiskRisk
  • 16. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients: EBTEBT 0 1 2 3 4 5 6 7 0 10 20 30 40 50 60 70 80 90 Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score LowLow RiskRisk IntermediateIntermediate RiskRisk HighHigh RiskRisk CRP CRP
  • 17. Clinical Questions in PreventionClinical Questions in Prevention In the asymptomatic individual How aggressive should I be?  Primary versus secondary prev. goals How closely should I follow up?  Routine versus close & repeat testing
  • 18. hs-CRP CAC Range Level of Aggression, f/u < 1 mg/L > 1-3 mg/L > 3 mg/L hs-CRP & CAC Scoringhs-CRP & CAC Scoring Value Range Percentile Range Aggression Clinical f/u Low Low Low Mod. Mod. Mod. High High High <25th Low >25th -<75th Intermed. >75th High <25th Low >25th -<75th Intermed. >75th High <25th Low >25th -<75th Intermed. >75th High Primary Routine Primary Routine Secondary Close Primary Routine Primary Close Secondary Close Primary Close Secondary Close Secondary Close
  • 19. hs-CRP & CAC Scoringhs-CRP & CAC Scoring In “intermediate” risk asymptomatic individualsIn “intermediate” risk asymptomatic individuals CAC Scanning with CTCAC Scanning with CT && hs-CRP testinghs-CRP testing areare ComplementaryComplementary to each otherto each other and the combination of bothand the combination of both can be used to refinecan be used to refine Clinical-Decision making in such patientsClinical-Decision making in such patients